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A B S T R A C T
The present work explores the application of melt granulation technology to develop a high
drug loaded sustained release matrix tablet of Metformin HCl using hydroxypropylcellulose
(HPC) as a hydrophilic binder and stearic acid as an extrusion aid for producing cohesive
granules. This novel approach allowed the use of a minimum number of excipients to reduce
the tablet size, and to enhance compressibility of the drug. This also offered a cost effec-
tive method owing to the elimination of a ‘drying step’ prevalent in wet granulation method.
Moreover, this research also focuses on resolving the processability issues associated with
the use of HPC Nisso-H at high drug loading. The thermal lubricants were screened for this
purpose and evaluated for their impact on extrudability, granule and tablet characteris-
tics. Stearic acid was selected as the thermal lubricant, which not only contributed to the
inhibition of burst release, but also improved the flow property of the granules.
The developed matrix tablet (75% drug loading) resulted in 670 mg of weight for 500 mg
dose strength and showed sustained drug release over 10 h. When compared, with conven-
tional granulation techniques, it was observed that, under identical compression force, the
tablet prepared by MG exhibited superior compactibility along with tablet hardness and optimal
drug release profile. FTIR suggested nonexistence of chemical interaction between the drug
and the other excipients while XRD and DSC analysis revealed the crystalline state of the drug.
Furthermore, the results obtained from Raman spectroscopy proved the uniform distribu-
tion of the Metformin HCl and polymer in the final dosage form. This technology leads to the
manufacture of sustained release matrix formulation with reduced tablet size of a high dose,
highly water soluble drug otherwise difficult to process using standard batch-granulation.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Keywords:
Metformin hydrochloride
Hydroxypropylcellulose
High drug loaded tablet
Melt granulation
* Corresponding author. Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University under Section
3 of UGC Act–1956, Elite Status and Centre of Excellence – Government of Maharashtra, Matunga (E), Mumbai, Maharashtra 400019, India.
Fax: +91 22 3361 1020.
E-mail address: purnima.amin@yahoo.co.in (P. Amin).
Peer review under responsibility of Shenyang Pharmaceutical University.
http://dx.doi.org/10.1016/j.ajps.2016.08.005
1818-0876/© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 3 7 – 5 0
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
ScienceDirect
1. Introduction
Conventionally, to achieve the sustained release profile of a
highly water soluble drug, it is necessary to use a large amount
of release-controlling polymers which in turn increases the
tablet weight [1–5]. Conversely, high-dose drug products require
minimal use of excipients to keep the tablet size small enough
to allow ease of swallowing. Metformin HCl is a highly water
soluble drug with high dose and also has significant process-
ing challenges due to its poor compressibility and moisture
sensitivity. In addition, Metformin HCl is commonly used in
combination with other hypoglycemic agents to develop a fixed
dose combination which makes the tablet size even larger and
might worsen its compactibility. Employing wet granulation
(WG) to overcome these challenges may result in formation
of solid bridges in Metformin HCl particles, poor powder flow
as well as sticking problems during tableting due to conse-
quent moisture migration or desorption during the granulation
process [6,7].
MG can be explored to overcome these formulation chal-
lenges of Metformin HCl. It is advantageous over traditional
granulation techniques as it is a solvent free green technology
with a closed process unit and easy to scale up. In addition, it
produces granules that contain fewer fines, reduces the number
of processing steps and requirements of inventory. Moreover,
in MG extensive solid bridges are formed between the drug and
excipient particles resulting in a smaller pore radius and a more
tortuous network, thereby facilitating densification of the molten
mass to a higher extent and a less porous matrix, thus capable
of reducing burst release in the early hours [8,9]. On this basis,
MG technology can be used to formulate sustained release matrix
with high drug loading of water soluble drugs.
Literature data have reported several approaches to formu-
late sustained release Metformin HCl. However, as per reports
to date, no literature data are available on the application of
continuous granulation process using hot melt extrusion to
develop sustained release formulation of Metformin HCl with
minimal use of excipients.
In this study, hydroxypropylcellulose (HPC) Nisso-H polymer
was used as meltable binder owing to its thermoplastic nature,
low softening point and high swelling capacity [10–13]. However,
these properties vary from manufacturer to manufacturer. Al-
though reports citing the use of HPC Klucel are available in
literature, the current research work further deals with the chal-
lenges of extruding HPC Nisso-H. It was observed that extrusion
of HPC Nisso-H by itself is very challenging and the chal-
lenge becomes even more difficult as the objective was to
extrude the blend with a high ratio of crystalline drug. Fur-
thermore, the research work deals with further development
of the extruded material into a sustained release tablet dosage
form.
Based on these premises, the present work aimed to explore
feasibility of MG technology to improve physiochemical prop-
erties of Metformin HCl such as poor flow and compressibility
and to formulate sustained release matrices with maximum
drug loading. For this purpose, the potential of HPC Nisso-H
was explored as a binder for sustained release formulation.
Moreover, the present work also comprises estimation of
robust manufacturing process for high-dose Metformin HCl
formulation by comparison of matrices prepared by MG and
other conventional granulation methods.
2. Materials and methods
2.1. Materials
Metformin HCl was purchased from Sohan Healthcare Pvt. Ltd.
(Pune, India). Hydroxypropylcellulose (HPC) Nisso H was pro-
vided by Nippon Soda Co. Ltd. (Tokyo, Japan) as a free sample.
Propylene glycol, Polyethylene glycol 400 (PEG 400), Polyethyl-
ene glycol 1500 (PEG 1500), Polyethylene glycol 4000 (PEG 4000),
Triethylcitrate (TEC), Stearic acid and Glyceryl monostearate
(GMS) were purchased from S.D. Fine Chemicals. All other ex-
cipients used were of analytical grade.
2.2. Preparation of matrix tablets
The drug and the thermoplastic binders were first delumped
by passing through #60 and mixed for 10 min to form a uniform
powder blend. The powder blends were processed using three
different methods like direct granulation (DG), wet granula-
tion (WG) and melt granulation (MG). The screened granules
obtained for various tablet formulations were compressed using
9 × 17 mm (drug loading: 50%) and 8 × 16 mm for higher drug
loading on a rotary tablet press (Rimek Minipress I, Ahmed-
abad, India).
2.2.1. Influence of thermal aid
To improve the processability of melt extrusion various thermal
aids were evaluated. Table 1 enlists the different thermal aids
screened and the concentration optimization.
2.2.2. Influence of drug loading
Tablet formulation comprising different drug loadings (50–
85%) was prepared using MG method. All the ingredients were
mixed as per the specified ratio (Table 2). The MG process was
performed using a laboratory scale, single screw hot melt ex-
truder (Lab Model, S.B. Panchal & Co.) equipped with a 100 mm
long and 20 mm diameter screw using the following param-
eters: processing temperature: 110 ± 2 °C (much below the
melting temperature of drug), screw speed: 50 rpm. The ob-
tained product was then cooled to ambient temperature and
subjected to milling and sieving through a screen of #40. The
powdered extrude was then subjected to tablet compression.
2.2.3. Effect of method of preparation
The tablet containing 75% loading of Metformin HCl was pre-
pared by different techniques like MG (F6), DG (F9) and WG (F10)
(Table 2). The MG process was carried out as mentioned above.
In DG, all ingredients were accurately weighed and passed
through a #60 sieve and mixed in geometric proportion for
10 min to form a uniform blend. For WG, water (8% w/w) was
sprinkled to form a wet mass which was passed through #20
to obtain granules, which were then subjected to drying at 40 °C
until the desired loss on drying (LOD) level (less than 2%) was
obtained.The blends prepared by different methods were com-
pressed to obtain tablets.
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2.3. Micromeritics of the formulation blend
The products obtained from all the batches were evaluated for
their physicochemical properties. The angle of repose (α) was
determined by the static funnel method and calculated using
the formula
tanθ = h r (1)
Bulk density (BD) was measured by filling a preweighed
100 ml glass cylinder to its capacity with the granules and then
weighing it. The tap density (TD) was calculated by dividing
the fill weight of the powder by its new reduced volume after
tapping it 100 times on a tap density apparatus. The com-
pressibility index (CI) and Hausner’s ratio (HR) were measured
by USP method I using a graduated cylinder and were calcu-
lated using the following formulas:
Compressibility Index CI
TD BD
TD
( ) = −( ) × 100 (2)
Hausner s Ratio HR
TD
BD
’ ( ) = (3)
2.4. Evaluation of tablets
2.4.1. Physical properties of tablets
The compressed tablets were evaluated for hardness, friabil-
ity, weight variation, thickness and content uniformity using
USP methods. Hardness (n = 10) was measured using a Dr.
Schleuniger 6D hardness tester (Schleuniger Pharmatron, New
Hampshire, USA) and friability (n = 10) was tested using a Roche
friabilator (F. Hoffmann-La Roche Ltd, Basel, Switzerland). The
dimensions of the tablets were determined using a Vernier
caliper (Mitutoyo Corp, Kawasaki, Japan). Tablet weight varia-
tion was evaluated by weighing individual tablets (n = 20) and
the variability (% RSD) in tablet weights was reported as percent
of average tablet weight. Individual tablets (n = 10) sampled from
each batch were individually assayed by a UV spectrophotom-
eter to determine the content uniformity.
2.4.2. Evaluation of in-vitro drug release
Dissolution testing was performed in accordance with the USP
31 monograph. 1000 ml of pH 6.8 phosphate buffer was used
as a dissolution medium at 37 °C by using a USP dissolution
test apparatus II (Electrolab, TDT-08L, India) at a paddle speed
of 50 rpm with sinkers. Sink condition was maintained through-
out the study. An aliquot of 10 ml was withdrawn at 1, 3, 5, 7
and 10 h intervals and replaced with the same amount of fresh
media. All the samples were filtered through a 0.45 μm filter
paper, appropriately diluted and analyzed for drug release spec-
trophotometrically (UV1650PC, Schimadzu Corporation, USA)
at λ max of 233 nm.The USP limits for a sustained release profile
of Metformin HCl are depicted in Table 3.
2.4.3. Kinetic analysis and mechanism of drug release
In order to elucidate the drug release mechanism from the ma-
trices of a solid dispersion tablet, release data of selected
Table 1 – Screening and optimization of concentration of thermal aid.
Ingredients Formulation code
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11
Metformin HCl 50 50 50 50 50 50 50 50 50 50 50
Hydroxypropylcellulose
HPC Nisso-H
40 40 40 40 40 40 40 45 43 38 35
Propylene glycol 10 – – – – – – – – – –
PEG 400 – 10 – – – – – – – – –
PEG 1500 – – 10 – – – – – – – –
PEG 4000 – – – 10 – – – – – – –
GMS – – – – 10 – – – – – –
TEC – – – – – 10 – – – – –
Stearic acid – – – – – – 10 5 7 12 15
All quantities are in percentage (w/w).
Table 2 – Composition of blend for SR matrix tablet
prepared by various methods and its process
parameters.
Ingredients Drug loading
F1 a F2a F3a F4a F5a F6a F7a F8a F9b F10c
Metformin HCl 50 55 60 65 70 75 80 85 75 75
HPC Nisso-H 40 35 30 25 20 15 10 5 15 15
Stearic acid 10 10 10 10 10 10 10 10 10 10
Purified water – – – – – – – – – q.s.d
Extrusion with
die
+ NA NA NA NA NA NA NA NA NA
Extrusion
without die
NA + + + + + + + NA NA
All quantities are in percentage (w/w).
a Melt granulation with HPC Nisso-H.
b Dry granulation with HPC Nisso-H.
c Wet granulation with HPC Nisso-H.
d Water used for granulation and removed by drying.
Table 3 – The USP limits for a sustained release profile
of Metformin HCl.
Time (h) USP limit
1 20%–40%
3 45%–65%
10 NLT 85%
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formulations were examined according to different math-
ematical equations such as Zero order (M = kt) equation, First-
order equation, (lnM = kt), Higuchi model (M = k√t) and
Korsemeyer–Peppas equation (Power law), (M = ktn). M is the
amount of drug (%) released after time t. k is the release rate
constant and n is the diffusional exponent. A value of n = 0.45
indicates case I (Fickian) diffusion, 0.45 < n < 0.89 anomalous
(non Fickian) diffusion, n = 0.89 for the case II transport and
n > 0.89 for the supercase II transport. The best fit was decided
on the basis of regression values [14].
In order to characterize the drug release process further time
point approach was used. With this approach, the mean dis-
solution time (MDT) was determined as it provides a more
accurate view of the drug release behavior. MDT is deter-
mined as the sum of the individual periods of time during
which a specific fraction of the total drug dose is released, cal-
culated using following equation [15]:
MDT
M
=
∞
Σ t
M
(4)
where Mt is the fraction of dose released in time ti, ti = (ti + ti−1)/
2, and M∞ corresponds to the loading dose.
In addition, to compare differences in the drug release
rate and extent among the prepared formulas, dissolution
efficiency (%DE) was calculated using the following equation.
%DE is defined as the area under the dissolution curve
up to the time “t,” expressed as percentage of the area of a
rectangle described by 100% dissolution in the same time
[16,17].
%DE
TY dt
Y T
=
×
×
×
∫0
100
100 (5)
where Y is the percent drug release as the function of time, t;
T is the total time of drug release and Y100 is 100% drug release.
2.4.4. Fit factors
Fit factors are composed of difference (f1) and similarity com-
ponents (f2) which compare and establish similarities and
differences between two dissolution curves obtained from a
set of experimental data [15,16]. For this study, f1 and f2 were
calculated by comparing in vitro drug release profiles ob-
tained under similar conditions of the formulations (test) with
the release profile of marketed SR tablet as reference (Gluformin
XR®, Abbott Healthcare Pvt Ltd, India). f1 measures the percent
error between the two curves over all time points and was cal-
culated by using Eq. (6).
f1 100= ( )[ ] ×Σ ΣR T Ri i i– (6)
where Ri and Ti are the percent dissolved of the reference and
test products at each time point i respectively.
ƒ2 was used to compare the dissolution behavior of repro-
ducibility batches and compared with that of marketed and
innovator’s products. f2 is a logarithmic transformation of the
sum of squared error of differences between the test Ti and
the reference products Ri over all time points. It was calcu-
lated by using Eq. (7).
f
n
R Ti i2
2
0 5
50 1
1
100= + ⎛⎝ ⎞⎠ −( )⎡⎣⎢
⎤
⎦⎥ ×
⎧⎨⎩
⎫⎬⎭∑
−
log
.
(7)
As per the recommendations made by the FDA Guidance
for Industry, an f2 value between 50 and 100 indicates simi-
larity between two dissolution profiles [15,18] and f1 values up
to 15 ensure sameness or equivalence of the test (post change)
and reference (pre-change) products.
2.4.5. Stability studies
The optimized formulations were stored in high density poly-
ethylene (HDPE) bottles and subjected to stability studies as
per International Conference on Harmonization (ICH) guide-
lines for a period of six months at 25 °C/RH 60%, 30 °C/RH 65%
and 40 °C/RH 75%, and were monitored for changes in physi-
cal attributes, drug content and in vitro release.
2.5. Characterization
2.5.1. Fourier-transform infrared (FTIR) analysis
FTIR studies were performed using a Perkin Elmer FTIR spec-
trophotometer (Spectrum RX1, USA) to investigate the
interaction of Metformin HCl with the polymer or plasticizer.
The samples were pelletized with KBr and the pellet was ana-
lyzed at a scanning range of 450–4000 cm−1. Change in
characteristic peaks of the respective samples was recorded.
2.5.2. Differential scanning calorimetry (DSC) analysis
DSC analysis was carried out using Perkin Elmer, Pyris 6 DSC
(Perkin Elmer life & Analytical Sciences Inc., USA) system in
the temperature range 30–250 °C at a heating rate of 10 °C/
min in a dynamic nitrogen atmosphere (18 ml/min). The
samples were ground into fine powders with a pestle and
mortar. Approximately 5 mg of sample was accurately weighed
and crimped in an aluminum lid, and an empty sealed alu-
minum pan was used as the reference.
2.5.3. X-ray diffraction analysis
X-ray diffraction (XRD) analysis was performed for raw mate-
rials, physical mixture and powdered extrudate using Bruker
AXS D8 Advance powder diffractometer (Germany) with Cu–
Kα radiation source (λ = 1.5406 A°) at 25 °C operated at 40 kV
and 40 mA, using a 0.02° step size and 2θ/min scan speed.
2.5.4. Scanning electron microscopy
The morphological characteristics of the matrix tablet pre-
pared by melt granulation, dry and wet granulations were
studied by scanning electron microscopy (Model JSM-6380LA,
JEOL, Japan).The samples were mounted on an aluminum stage
using adhesive carbon tape and were coated with a platinum
plasma beam using JFC-1600 auto fine coater to make a layer
of 2 nm thickness above the sample. Scanning electron mi-
crophotographs were obtained by applying electron current
under a voltage difference of 20 kV.
2.5.5. Raman spectral analysis
The Raman spectra of the individual components of the tablet
formulation (Metformin HCl, HPC Nisso-H and stearic acid) along
with that of the optimized formulation were recorded with a
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LabRamHR800 (Horiba Jovan Yvon). The spectrometer was
equipped with a 1800 groove/mm holographic grating, a ho-
lographic notch filter and a Peltier-cooled charge-coupled device
(CCD, Andor Technology PLC), which was employed as a de-
tector. The laser excitation was focused using a microscope
objective of 50× (Olympus Corporation). An Ar:Ne laser was em-
ployed during the experiments with a wavelength of 633 nm.
Raman spectroscopic imaging or mapping was used to evalu-
ate the distribution of Metformin HCl in the matrix tablet
prepared by melt granulation.
3. Results and discussion
3.1. Preparation of matrix tablets
3.1.1. Influence of thermal aid
Sustained release matrix formulation of a high dose drug poses
a major challenge of maintaining the polymer matrix integ-
rity since the release rate is dependent on it. The processing
temperature should be above the Tg or melting temperature
of the polymeric carrier and typically required to soften the
polymer by lowering its melt viscosity which allows ad-
equate flow through the extruder. However, it was evident from
preliminary experiments that the HPC Nisso-H was difficult to
extrude and required thermal aid to ease the granulation
process. So, the initial challenge was to plasticize HPC Nisso-H
to overcome processing of the powder blend with high ratio
of the drug. In order to extrude HPC Nisso-H, various thermal
aids were studied at a concentration of 10% w/w.
Parameters for screening the thermal aid for melt granu-
lation include ease of granulation, powder and tablet properties
and dissolution profile. Though thermal aid like Propylene
Glycol, PEG 400 and TEC showed an effective plasticizing effect
in the extrusion process, the pulverized powder of the
extrudates showed poor compressibility with sticking problem
due to hygroscopicity. Moreover, these thermal aids were unable
to retard drug release sufficient to ensure a sustained release
profile of Metformin HCl within USP limits, due to its hydro-
philic nature (Fig. 1A). In case of PEG 1500 and PEG 4000, the
high molecular weight of these plasticizers may interfere in
the melting of physical mixture, and hence did not act as good
plasticizers in the presence of Metformin HCl. In contrast, stearic
acid as a solid thermal aid was easy to process since it blended
easily with the polymer and the drug, and unlike liquid thermal
aids, it did not make a tacky blend with HPC Nisso-H, which
is difficult to feed in the extruder uniformly. Further, extru-
sion of the blend with 10% stearic acid was carried out without
producing any torque on machine with processing tempera-
ture of 110 °C ± 2 °C. In addition, the extrudates obtained were
easy to pulverize and the powder of the extrudates was not
hygroscopic at all and gave excellent flow.
In order to evaluate the optimum concentration of stearic
acid as thermal aid for the extrusion process, trial batches were
prepared with different concentrations. At 15% concentra-
tion of stearic acid, the material was discharged as soft rubbery
extrudate resulting from the lowering of the viscosity of the
mixture at the increased fatty acid level. These extrudates re-
mained soft even after cooling at ambient temperature and were
not suitable for milling. At the levels of 12%, 10% and 7% of
stearic acid, extrudates were found to be suitable for extru-
sion without creating any excess friction and forming soft
rubbery extrusions. The powder blend extruded smoothly, and
the obtained extrudates were sufficiently brittle for milling.
However, it was observed that the increase in drug loading was
not supported by 7% of the stearic acid and higher amounts
of it were required. Both 10% and 12% concentrations of stearic
acid underwent extrusion at 110 ± 2 °C, however considering
the objective of high drug loading, 10% stearic acid concen-
tration was fixed for further study.
3.1.2. Influence of drug loading
MG was performed by varying drug loading (50–85%) to inves-
tigate the feasibility of loading higher concentrations of the
drug. The formulation containing 85% drug load resulted in ex-
cessive friction between the screw and wall of the barrel, and
the powder blend was not discharged. The extrudability of the
material is generally characterized by extrusion torque during
the process, the material output rate and the physical appear-
ance of the extrudes. Initial processability trials in the absences
of a plasticizer with 50% drug loading resulted in charring of
HPC Nisso-H in physical mixture due to the long residence time
and exposure to heat. This trial indicated that melt granula-
tion with HPC Nisso-H leads to poor extrudability and hence
mandates the use of a plasticizer for ease of extrusion purpose.
The flow properties of the optimized formulation are pre-
sented in Table 4. The angle of repose of the melt granulated
formulation (F6) showed excellent flowability (25 < angle of
repose < 30). Further, Carr’s index and Hausner’s ratio of melt
granulated formulation (F6) are between 10.0 and 18.0% and
less than 1.25 respectively, confirming the good flow of gran-
ules. It indicates that the addition of stearic acid not only served
as a thermal lubricant, but also improved the flow property of
the granules, thereby avoiding capping and sticking prob-
lems. This obviated the need for further lubrication of granules
with magnesium stearate or talc and helped to reduce tablet
weight further.
The effect of drug loading on tablet properties is depicted
in Table 5.The data demonstrate that tablets of all batches with
successive increase in drug loading had friability and weight
variation within acceptable limits and a tablet hardness range
of 14–17 kN. Overall, tablets with reduced weight and dimen-
sions and with improved hardness and friability have been
achievable by performing melt granulation with a single screw
extruder at an extruder speed of 50 rpm, and using a combi-
nation of HPC Nisso-H with 10% stearic acid at the temperature
(110 ± 2 °C). Further, all the formulations processed by melt
granulation showed drug content of >96%. This is indicative
of a robust formulation and process. The dissolution profile of
Metformin HCl from matrices containing varying drug load-
ings is shown in Fig. 1B. As seen in Fig. 1B, the drug release
profiles were greatly influenced by the amount of drug loading.
By simply combining a water-insoluble retardant like stearic
acid and a water-soluble polymer, HPC Nisso-H, the extent of
release retardation was modified. Interestingly, as seen in Fig. 1B,
the dissolution profile at different levels of drug loading showed
that loading up to a level of 80% was feasible and gave release
profiles within USP limits. However, at the level of 80%, the drug
release profile was found to be on the higher range of the USP
limit. At a 75% w/w drug loading it can be reasonably
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expected that numerous and large channels will rapidly develop
as the matrix tablet hydrates. If there is a sufficient polymer
within the matrix to maintain structural integrity and prevent
tablet disintegration, then rapid drug dissolution and diffu-
sion of the Metformin HCl can be overcome. It may, however,
be possible that when used in combination, HPC Nisso-H might
have swollen within the porous shell of stearic acid, thereby
creating a more effective barrier for drug release. In addition,
it has been also reported that melt extrusion resulted in a lower
free-volume, a small pore radius, and a more tortuous pore
network of the extrudates, thus reducing the drug release rates
[8,19]. On the basis of these data, 75% drug loading with 10%
Fig. 1 – Effect on dissolution profile of Metformin HCl: (A) due to different thermal aids, (B) due to different drug loadings, (C)
due to different methods of granulation and (D) comparison of optimized formulation with marketed tablet.
Table 4 – Micromeritics of the pre-compression blend prepared by different granulation processes with HPC Nisso-H.
Properties Metformin HCl F6 F9 F10
Angle of repose (o) Very very poor 23.91 ± 0.61 38.89 ± 0.42 32.65 ± 0.58
Bulk density (g/ml) 0.4545 ± 0.082 0.4376 ± 0.012 0.4219 ± 0.029 0.4444 ± 0.020
Tapped density (g/ml) 0.6667 ± 0.031 0.5217 ± 0.017 0.5732 ± 0.021 0.5882 ± 0.038
Carr’s index 31.82 ± 9.15 16.11 ± 0.434 26.45 ± 2.366 24.38 ± 1.488
Hausner ratio 1.49 ± 0.204 1.19 ± 0.006 1.36 ± 0.044 1.32 ± 0.026
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stearic acid and 15% HPC Nisso-H as a binder was chosen to
minimize the overall tablet size while still achieving accept-
ably robust tableting properties.
3.1.3. Effect of method of preparation
At higher drug loading (75%), the method of granulation has
an effect on granule flowability and compactability, which
further affects the die filling and tablet mechanical charac-
teristics. Hence, the micromeritic properties of granules were
evaluated and presented in Table 4. The flow of granules pre-
pared by DG (F9) and WG (F10) was poor even in the presence
of stearic acid, and hence additional lubrication was em-
ployed by the addition of magnesium stearate and talc. On this
basis, it can be concluded that MG (F6) showed improved flow
properties and compressibility in comparison with DG (F9) and
WG (F10). The dissolution profiles of tablets prepared by wet,
dry and melt granulations using Nisso HPC-H can be seen in
Fig. 1C. Tablet prepared by WG (F10) and DG (F9) techniques
showed 42.19% and 63.12% drug release within one hour re-
spectively. At the end of 5 hours more than 90% of the drug
was released from these tablets due to poor matrix integrity
and high porosity. It was observed that the conventional wet
granulation method was not a robust one at such a high drug
loading of Metformin HCl. Granules prepared by wet massing
consisted of intact drug particles held together in a sponge-
like matrix of the binder of HPC Nisso-H and stearic acid.
However, drug loading to a level of 75% resulted in tablets with
greater porosity and failed to form a smooth, even surface.This
theory confirmed the latter by scanning electron microscopy
analysis. Similar observations can be made with tablets pre-
pared by DG technique. Properties of the tablet produced by
MG, WG and DG processes are mentioned in Table 5. It indi-
cates that tablets prepared by the MG process are relatively hard
with less moisture content. It is clear that MG is superior to
WG and DG as it allowed for substantially better compaction
profile, friability and dissolution profile. MG was clearly supe-
rior to WG and DG. Fig. 1D shows the comparative dissolution
profile of optimized (F6) and marketed formulations. The op-
timized formulation provided the release profile within USP
limit and was found to be comparable with that of marketed
formulation.
3.2. Kinetic analysis and mechanism of drug release
To interpret the mechanism of drug release from these for-
mulations, the data were subjected to different mathematical
models, such as zero-order, First-order, and Higuchi’s and
Korsmeyer’s equations. In Table 6, the kinetic parameters for
Metformin HCl release from the matrix tablets are presented.
It revealed that in vitro release profiles of drugs from the for-
mulations with successive loading (F1–F7) follow Higuchi’s
release model as the plots showed high linearity (Rh2: 0.9895–
0.9981). Drug release from a matrix tablet containing hydrophilic
polymers generally follows diffusion. Diffusion is related to
transport of the drug from the dosage matrix into the in vitro
dissolution medium depending on the concentration. As the
concentration gradient varies, the drug is released, and the dis-
tance for diffusion increases. This may possibly explain drug
diffusion at a comparatively slower rate as the distance for dif-
fusion increases, which is referred to as square root kinetics
or Higuchi’s kinetics. To confirm the diffusion mechanism, the
data were fitted into Korsmeyer’s equation to calculate np values
[20]. In our experiments, the formulations (F1–F7) showed np
values ranging from 0.553 to 0.431, indicating that the diffusion
Table 5 – Properties of tablets produced by the melt granulation process with various drug loadings.
Formulation
code
Tablet properties
Weight
(mg)a
Dimensions (L × B × T)
(mm)b
Hardness
(kN)b
Friability
(%)b
Assay
(%)b
Moisture
contentb (%)
L B T
F1 1015.8 ± 2.65 17.71 ± 0.01 9.51 ± 0.02 6.62 ± 0.01 16.53 ± 0.26 0.32 ± 0.31 97.22 ± 1.89 0.572 ± 0.06
F2 920.34 ± 2.46 16.84 ± 0.03 8.94 ± 0.02 7.23 ± 0.02 14.97 ± 0.58 0.38 ± 0.26 99.63 ± 0.61 0.688 ± 0.01
F3 844.17 ± 3.39 16.88 ± 0.01 9.07 ± 0.03 6.92 ± 0.02 15.08 ± 0.65 0.27 ± 0.21 98.93 ± 0.47 0.739 ± 0.02
F4 779.77 ± 3.47 16.90 ± 0.03 8.97 ± 0.02 5.99 ± 0.04 15.54 ± 0.36 0.39 ± 0.36 96.32 ± 1.12 0.489 ± 0.03
F5 732.06 ± 5.63 16.89 ± 0.03 8.96 ± 0.03 5.46 ± 0.02 16.42 ± 0.40 0.28 ± 0.18 97.38 ± 0.71 0.871 ± 0.07
F6 669.93 ± 2.48 16.91 ± 0.02 8.95 ± 0.05 5.20 ± 0.02 15.51 ± 0.39 0.23 ± 0.29 99.09 ± 1.07 0.792 ± 0.03
F7 635.15 ± 3.27 16.90 ± 0.02 8.99 ± 0.01 4.84 ± 0.04 14.48 ± 0.97 0.28 ± 0.21 98.93 ± 1.33 0.972 ± 0.05
F9 680.65 ± 7.79 16.96 ± 0.01 8.97 ± 0.01 5.24 ± 0.01 7.46 ± 0.28 1.85 ± 1.31 99.17 ± 1.58 1.894 ± 0.13
F10 679.41 ± 7.20 16.96 ± 0.01 9.02 ± 0.02 5.19 ± 0.02 12.95 ± 0.34 0.81 ± 1.14 97.23 ± 1.36 2.172 ± 0.31
Marketed tablet 753.80 ± 5.21 16.09 ± 0.03 8.10 ± 0.04 6.45 ± 0.02 14.02 ± 0.16 0.17 ± 0.11 97.31 ± 1.19 –
a ± Standard deviation, n = 20.
b ± Standard deviation, n = 10.
Table 6 – Data from regression fitting between
dissolution profiles (obtained from different matrix
tablets prepared by different methods and several
kinetic models).
Formulation
code
Parameters of model dependent factors
Zero First Higuchi Korsmeyer–Peppas
R02 R12 Rh2 Rp2 np
F1 0.8664 0.9805 0.9953 0.9981 0.553
F2 0.8221 0.9799 0.9974 0.9975 0.509
F3 0.8025 0.9823 0.9981 0.9982 0.492
F4 0.7740 0.9855 0.9968 0.9979 0.470
F5 0.7665 0.9893 0.9953 0.9968 0.466
F6 0.7337 0.989 0.992 0.9963 0.442
F7 0.7173 0.9873 0.9895 0.9958 0.431
F9 0.3825 0.9962 0.6327 0.9756 0.376
F10 0.3009 0.9866 0.9326 0.9756 0.376
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is the dominant mechanism of drug release from these for-
mulations. Further, np values were decreasing for the successive
increase in drug loading, which indicates a direct relation-
ship of np values with the concentration of HPC Nisso-H. For
matrix tablets, an np value of near 0.5 indicates diffusion control,
and an np value of near 1.0 indicates erosion or relaxation
control. Intermediate values suggest that diffusion and erosion
contribute to the overall release mechanism [21].
The np values for F1–F4 are ranged 0.509–0.466, indicating
a non-Fickian/anomalous diffusion (0.45 < np < 0.89), and tablets
of F5 (np = 0.466), F6 (np = 0.442) and F7 (np = 0.431) follow a Fickian
diffusion during the entire period of drug release (10 h). The
principle of diffusion is based on Fick’s laws, which illustrate
the macroscopic transport of molecules by a concentration gra-
dient. Drug release from the matrix tablet generally follows
diffusion for water-soluble drugs and erosion or relaxation for
water insoluble drugs.
The dissolution model independent factors (MDT, h, and
%DE) were calculated by analyzing in vitro dissolution data of
all batches and considering the release profile of marketed
tablets as reference (Table 7). Dissolution efficiency (%DE) and
mean dissolution time (MDT, h) were used as the criteria for
comparing the effect of different granulation methods on the
drug release profile. %DE values for tablets prepared by MG were
remarkably less as compared to tablets prepared by other
granulation methods. The %DE and MDT (h) values for F6
(%DE = 66.364, MDT = 2.953 h) formulations were comparable
with the reference tablet (%DE = 60.584, MDT = 3.305 h). Hence,
by comparing the %DE and MDT of the different formula-
tions, it was clear that drug release was effectively controlled
by melt granulation process.
3.3. Fit factors
The results of similarity (f2) and difference (f1) factors (Table 7)
revealed that the drug release profile of tablets prepared by melt
granulation method F6 (f1 = 9.369 and f2 = 61.986) was found to
be best fitted to the drug release profile of the reference tablet
(marketed tablet) compared to tablets prepared by WG and DG.
3.4. Stability study
The optimized formulation was found to be stable after six
months as per ICH guidelines with no significant changes in
dissolution behavior (Fig. 2), drug content (Table 8) and physi-
cal stability.
3.5. Characterization
3.5.1. Fourier-transform infrared analysis (FTIR)
Fig. 3A–C shows the FTIR spectra of pure Metformin HCl, HPC
Nisso-H and stearic acid respectively. Metformin HCl (Fig. 3A),
Table 7 – Analysis of in vitro dissolution data (model
independent factors).
Parameter F6 F9 F10 Reference
MDT (h) 2.953 1.135 2.025 3.305
%DE 66.364 88.910 80.238 60.584
f1 9.369 45.183 30.764 –
f2 61.986 27.658 36.449 –
Fig. 2 – Dissolution profile of Metformin HCl at initial and
after 1, 3, 6 months: (A) at 25 °C ± 2 °C/RH 60 ± 5%, (B) at
30 °C ± 2 °C/RH 65 ± 5% and (C) at 40 °C ± 2 °C/RH 75 ± 5%.
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being a biguanide, has strong absorption bands at 1634, 1573,
and 1562 cm−1 due to the presence of C—N stretching vibra-
tions. It has been reported that C—N stretching of aliphatic
diamine is generally weak and occurs in the region of 1220–
020 cm−1. Hence, weak intensity bands were found at 1062 and
1242 cm−1. N—H stretching of C—N—H groups occurs in the
region of 3400–3100 cm−1. So medium intensity peaks ap-
peared in the region of 3369, 3292, 3169, and 3153 cm−1
respectively because of N—H asymmetric and symmetric
stretching vibrations. Fig. 3D and E shows the infrared spec-
trum of physical mixture and optimized formulation (F6)
respectively. Fig. 3E reveals all the characteristic peaks of
Metformin HCl, which clearly shows the nonexistence of any
chemical interaction between the drug and the other excipients
even at elevated operating temperatures during the melt granu-
lation process.
3.5.2. Differential scanning calorimetry (DSC)
DSC analyses were performed in order to evaluate possible solid-
state interactions between the components and, consequently,
to assess the actual drug–excipient compatibility in all the ex-
amined formulations. As shown in Fig. 4A, the melting point
depression of pure Metformin HCl was 234.54 °C.The onset and
end of the endothermic peak were observed at 231.28 °C and
237.65 °C respectively. The DSC plot of physical mixture of
Metformin HCl, stearic acid and HPC Nisso-H (Fig. 4B) showed
two distinct endothermic peaks of Metformin HCl at 233.12 °C
and stearic acid at 53.38 °C respectively. The DSC plot of melt
granulated extrudes (F6) (Fig. 4C) did not exhibit any signifi-
cant difference near the melting endotherm of the individual
component.The endothermic peak of Metformin HCl (233.73 °C)
and stearic acid (56.93 °C) did not show any significant change
in melting point, however the peak height of Metformin HCl
was observed to reduce which likely reflects the slight melting
point depression. This reveals that there was a partial conver-
sion of the crystalline drug into an amorphous form; in other
words crystallinity of the drug reduced, but still the presence
of the crystalline drug after MG resulted in a two-phase solid
Table 8 – Effect of storage on tablet prepared by melt
granulation with HPC Nisso-H.
Parameter 25 °C/RH 60% 30 °C/RH 65% 40 °C/RH 75%
Drug content (%) 98.23 ± 1.95 99.40 + 0.80 97.73 ± 1.14
Moisture (%) 0.99 ± 0.21 0.91 ± 0.09 1.28 ± 0.18
Hardness(kN) 14.63 ± 0.61 14.93 ± 0.64 15.1 ± 0.7
Friability (%) 0.23 0.33 0.21
Fig. 3 – FTIR spectrum of (A) Metformin HCl, (B) HPC Nisso-H, (C) stearic acid, (D) physical mixture and (E) melt granulated
extrudes.
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Fig. 4 – Differential scanning calorimetry thermograms of (A) pure Metformin HCl, (B) physical mixtures and (C) melt
granulated powdered granules.
Fig. 5 – X-ray diffraction profiles of (A) HPC Nisso-H, (B) Metformin HCl, (C) physical mixture and (D) melt granulated
extrudes.
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dispersion in which Metformin HCl was present in both amor-
phous and crystalline forms, but no evidence of any other
physicochemical interaction was observed. However, there is
no conversion of crystalline drug substance to amorphous form
[22,23].
3.5.3. Powder X-ray diffraction studies (PXRD)
The X-ray diffraction patterns of pure Metformin HCl, HPC
Nisso-H, physical mixture and powdered extrudes are shown
in Fig. 5. The XRD of plain HPC Nisso-H showed (Fig. 5A) an
amorphous state as indicated by the presence of a back-
ground bump in the powder X-ray diffraction (PXRD).
Background bump is often indicative of the non-crystalline com-
position of a material, whereas peak position describes the
phases present in the sample. Pure Metformin HCl (Fig. 5B)
showed peaks at 2θ values of 6.94, 5.01, 3.96, 3.82, and 3.50, sig-
nifying the presence of a highly crystalline nature, which is
in good agreement with literature values. The crystallinity of
Metformin HCl was found to progressively decrease from pure
Metformin HCl, physical mixture (Fig. 5C) to melt granulated
extrudates (Fig. 5D) indicated by a low peak intensity. This
reveals that the melt granulation process decreased the
crystallinity of Metformin HCl in the powdered extrudates as
an effect of high shear mixing of melted physical mixture with
amorphous HPC Nisso-H, resulting in improved compressibil-
ity even at such a high drug loading.
3.5.4. Scanning electron microscopy
The present study of scanning electron microscopy images re-
vealed microstructures of the surfaces and interiors of a
sustained release tablet of Metformin HCl prepared by three
different granulation techniques. It was observed that tablets
prepared by DG and WG processes failed to produce a smooth
surface area at such high drug loading (75%). This can be elu-
cidated from the uneven surface and cracks present on the
surfaces of the tablet (Fig. 6A, B, E, F). Also, a cross sectional
view of these tablets showed a sufficiently high porous network
with large void spaces (Fig. 6C, D, G, H). In contrast, tablets pre-
pared by MG (Fig. 6I, J, K, L) with a single screw extruder possess
a densified material with improved compressibility of the drug,
which resulted in a tablet with a smooth surface area and less
void spaces. On the basis of these observations, it can be con-
cluded that at high drug loading due to the compressibility issue
of Metformin HCl, tablets prepared with DG or WG were unable
to maintain their integrity for a long period of time and failed
to retard the drug profile.
Fig. 6 – Dry granulation surface area: (A) at 100×, (B) at 500×, and cross sectional area: (C) at 100×, (D) at 500×. Wet granulation
surface area: (E) at 100×, (F) at 500×, and cross sectional area: (G) at 100×, (H) at 500×. Melt granulation surface area: (I) at
100×, (J) at 500×, and cross sectional area: (K) at 100×, (L) at 500×.
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Fig. 7 – (A) Raman spectra of pure reference materials: Metformin HCl, HPC Nisso-H, stearic acid and (B) distribution
mapping of the melt granulation tablet of optimized formulation.
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3.5.5. Raman spectral analysis
In the present study, Raman spectroscopy was applied to evalu-
ate the drug distribution in the matrix tablet. Fig. 7A illustrates
the Raman spectra of individual components of optimized for-
mulation. The spectrum of Metformin HCL displayed intense
bands at 425 cm−1, 739 cm−1and 938 cm−1, whereas stearic acid
and HPC Nisso-H had a different spectral profile from that of
Metformin HCl. These peaks of Metformin HCl were moni-
tored to map the distribution of the drug in the matrix because
there were no spectral interferences from the other excipi-
ents in this region. Fig. 7B displays their concentration
distribution, wherein the more reddish areas correspond to
higher concentration and the bluish color signifies lower con-
centration. Interestingly, the concentration map of the melt
granulation processed tablet showed better uniformity and dis-
tribution of the tablet’s components, suggesting very high
mixing efficiency at such a high drug loading. In addition,
Raman spectroscopy confirmed the existence of crystalline
Metformin HCl in the matrix, and such an intimate distribu-
tion of the drug and excipients appears to be responsible for
better compactibility and sustained release profile of Metformin
HCl.
4. Conclusion
The present study showed that reduction in tablet weight can
be achieved by higher drug loading (75%) to prepare Metformin
HCl 670 mg sustained release tablets. Such a formulation will
lead to improved patience compliance due to ease of swal-
lowing. Combination of cellulose based hydrophilic binder with
hydrophobic excipient can be successfully employed to for-
mulate a sustained release matrix tablet of Metformin HCl using
MG technology. Addition of stearic acid lubricates the extru-
sion screw, thereby decreasing the pressure on the machine.
Additionally, intense mixing of stearic acid with HPC Nisso-H
and the drug resulted in effective lubrication of the blend
thereby ruling out the need for other excipients to lubricate
the granules or enhance compactibility of the drug sub-
stance. Moreover, the MG process decreases the number of the
processing steps as granules obtained after melt granulation
were subjected to only milling before compression. This can
substantially reduce the manufacturing cost of tablets due to
the use of lesser excipients and unit operations. In addition,
the superiority of MG technology with enhanced sustained
effect was also apparent from its comparison with the con-
ventional granulation methods with equivalent composition.
In light of the above discussion, MG technology holds signifi-
cant potential as a continuous granulation process to develop
a sustained release system for highly water soluble drugs with
minimal use of excipients.
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